Vesicare Filmuhúðuð tafla 10 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

vesicare filmuhúðuð tafla 10 mg

astellas pharma a/s* - solifenacinum súkkínat - filmuhúðuð tafla - 10 mg

Vesicare Mixtúra, dreifa 1 mg/ml Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

vesicare mixtúra, dreifa 1 mg/ml

astellas pharma a/s* - solifenacinum súkkínat - mixtúra, dreifa - 1 mg/ml

Prograf Hart hylki 0,5 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

prograf hart hylki 0,5 mg

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 0,5 mg

Prograf Hart hylki 1 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

prograf hart hylki 1 mg

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 1 mg

Prograf Hart hylki 5 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

prograf hart hylki 5 mg

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 5 mg

Eligard Stungulyfsstofn og leysir, lausn 7,5 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

eligard stungulyfsstofn og leysir, lausn 7,5 mg

recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 7,5 mg

Eligard Stungulyfsstofn og leysir, lausn 45 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

eligard stungulyfsstofn og leysir, lausn 45 mg

recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 45 mg

Eligard Stungulyfsstofn og leysir, lausn 22,5 mg Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

eligard stungulyfsstofn og leysir, lausn 22,5 mg

recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 22,5 mg

Bendamustine Accord Stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

bendamustine accord stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml

accord healthcare b.v. - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml

Protopic Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

protopic

leo pharma a/s - takrólímus - dermatitis, atópísk - aðrar húðsjúkdómar - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. koma fjórir eða meira sinnum á ári) sem hafa haft fyrstu viðbrögð við sex vikur meðferð tvisvar á dag takrólímus smyrslið (sár ruddi, næstum ruddi eða dálítið áhrifum).